Atterocor Expands Trial Of New Drug To More Adrenal Cancer Centers
ANN ARBOR — The Ann Arbor adrenal cancer therapy developer Atterocor Inc. announced it had expanded its Phase 1 trial of ATR-101, an investigational therapy for the treatment of adrenocortical …